{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:16:36Z","timestamp":1785017796328,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,4]]},"DOI":"10.7759\/cureus.21919","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T04:46:19Z","timestamp":1644036379000},"source":"Crossref","is-referenced-by-count":12,"title":["Neurological Conditions Following COVID-19 Vaccinations: Chance or Association?"],"prefix":"10.7759","author":[{"given":"Josaiah","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheneel","family":"Jaggernauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Ramnarine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed R","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenelle","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avidesh","family":"Panday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Timeline - COVID-19. (2021). Accessed. October 1, 2021: https:\/\/www.who.int\/news\/item\/27-04-2020-who-timeline---covid-19."},{"key":"ref2","unstructured":"Worldometer. (2021). Accessed. October 25, 2021: https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref3","unstructured":"COVID-19 Advice for the Public. Getting Vaccinated. (2022). Accessed: January 26, 2022: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26065","article-title":"ANA investigates: neurological complications of COVID-19 vaccines","volume":"89","author":"Goss AL","year":"2021","unstructured":"Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021, 89:856-7. 10.1002\/ana.26065","journal-title":"Ann Neurol"},{"key":"ref5","unstructured":"Possible Side Effects After Getting a COVID-19 Vaccine. (2021). Accessed. October 25, 2021: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis D","year":"2014","unstructured":"Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014, 13:215-24. 10.1016\/j.autrev.2013.10.003","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977","volume":"110","author":"Schonberger LB","year":"1979","unstructured":"Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al.. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979, 110:105-23. 10.1093\/oxfordjournals.aje.a112795","journal-title":"Am J Epidemiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05662-9","article-title":"Spectrum of neurological complications following COVID-19 vaccination","volume":"43","author":"Garg RK","year":"2022","unstructured":"Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022, 43:3-40. 10.1007\/s10072-021-05662-9","journal-title":"Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13550","article-title":"Neurological side effects of SARS-CoV-2 vaccinations","volume":"145","author":"Finsterer J","year":"2022","unstructured":"Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022, 145:5-9. 10.1111\/ane.13550","journal-title":"Acta Neurol Scand"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200206000-00018","article-title":"Neurological adverse events associated with vaccination","volume":"15","author":"Piyasirisilp S","year":"2002","unstructured":"Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol. 2002, 15:333-8. 10.1097\/00019052-200206000-00018","journal-title":"Curr Opin Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106887","article-title":"Guillain-Barr\u00e9\u00a0syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association?","volume":"208","author":"Introna A","year":"2021","unstructured":"Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, Trojano M. Guillain-Barr\u00e9\u00a0syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association?. Clin Neurol Neurosurg. 2021, 208:106887. 10.1016\/j.clineuro.2021.106887","journal-title":"Clin Neurol Neurosurg"},{"key":"ref12","unstructured":"Causality assessment of an adverse event following immunization (\u200eAEFI)\u200e. user manual for the revised WHO classification, 2nd ed. (2022). Accessed: January 12, 2022: https:\/\/apps.who.int\/iris\/handle\/10665\/259959."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3816767","article-title":"COVID-19 vaccination acceptance among healthcare workers and nonhealthcare workers in China: a survey [Preprint]","author":"Wang MW","year":"2021","unstructured":"Wang MW, Wen W, Wang N, et al.. COVID-19 vaccination acceptance among healthcare workers and nonhealthcare workers in China: a survey [Preprint]. Lancet. 2021, 10.2139\/ssrn.3816767","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103701","article-title":"Neurological syndromes associated with anti-GAD antibodies","volume":"21","author":"Dade M","year":"2020","unstructured":"Dade M, Berzero G, Izquierdo C, et al.. Neurological syndromes associated with anti-GAD antibodies. Int J Mol Sci. 2020, 21:3701. 10.3390\/ijms21103701","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/347151a0","article-title":"Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase","volume":"347","author":"Baekkeskov S","year":"1990","unstructured":"Baekkeskov S, Aanstoot HJ, Christgau S, et al.. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990, 347:151-6. 10.1038\/347151a0","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif A","year":"2018","unstructured":"Daif A, Lukas RV, Issa NP, et al.. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018, 80:331-6. 10.1016\/j.yebeh.2018.01.021","journal-title":"Epilepsy Behav"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2020.100396","article-title":"Super refractory status epilepticus secondary to anti-GAD antibody encephalitis successfully treated with aggressive immunotherapy","volume":"14","author":"Jaafar F","year":"2020","unstructured":"Jaafar F, Haddad L, Koleilat N, Sharara-Chami R, Shbarou R. Super refractory status epilepticus secondary to anti-GAD antibody encephalitis successfully treated with aggressive immunotherapy. Epilepsy Behav Rep. 2020, 14:100396. 10.1016\/j.ebr.2020.100396","journal-title":"Epilepsy Behav Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-2-155","article-title":"Acute encephalitis - diagnosis and management","volume":"18","author":"Ellul M","year":"2018","unstructured":"Ellul M, Solomon T. Acute encephalitis - diagnosis and management. Clin Med (Lond). 2018, 18:155-9. 10.7861\/clinmedicine.18-2-155","journal-title":"Clin Med (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26182","article-title":"Postvaccinal encephalitis after ChAdOx1 nCov-19","volume":"90","author":"Zuhorn F","year":"2021","unstructured":"Zuhorn F, Graf T, Klingebiel R, Sch\u00e4bitz WR, Rogalewski A. Postvaccinal encephalitis after ChAdOx1 nCov-19. Ann Neurol. 2021, 90:506-11. 10.1002\/ana.26182","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","year":"2002","unstructured":"Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002, 59.499-505. 10.1212\/wnl.59.4.499","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2012.09.008","article-title":"Transverse myelitis","volume":"31","author":"Beh SC","year":"2013","unstructured":"Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin. 2013, 31:79-138. 10.1016\/j.ncl.2012.09.008","journal-title":"Neurol Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3841558","article-title":"Sudden onset of myelitis after COVID-19 vaccination: an under-recognized severe rare adverse event","author":"Fitzsimmons W","year":"2021","unstructured":"Fitzsimmons W, Nance CS. Sudden onset of myelitis after COVID-19 vaccination: an under-recognized severe rare adverse event. SSRN. 2021, 10.2139\/ssrn.3841558","journal-title":"SSRN"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Clemens SA, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"ref24","article-title":"Guillain-Barr\u00e9 syndrome","volume":"87","author":"Walling AD","year":"2013","unstructured":"Walling AD, Dickson G. Guillain-Barr\u00e9 syndrome. Am Fam Physician. 2013, 87:191-7.","journal-title":"Am Fam Physician"},{"key":"ref25","unstructured":"Global Medical Advisory Board (GMAB) Statement on Vaccines October 13th, 2021. (2021). Accessed. October 25, 2021: https:\/\/www.gbs-cidp.org\/covid-19-vaccines-and-the-gbscidp-community\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0897-6","article-title":"Meningitis-retention syndrome. An unrecognized clinical condition","volume":"252","author":"Sakakibara R","year":"2005","unstructured":"Sakakibara R, Uchiyama T, Liu Z, et al.. Meningitis-retention syndrome. An unrecognized clinical condition. J Neurol. 2005, 252:1495-9. 10.1007\/s00415-005-0897-6","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22279","article-title":"\"Meningitis-retention syndrome\": a review","volume":"32","author":"Sakakibara R","year":"2013","unstructured":"Sakakibara R, Kishi M, Tsuyusaki Y, et al.. \"Meningitis-retention syndrome\": a review. Neurourol Urodyn. 2013, 32:19-23. 10.1002\/nau.22279","journal-title":"Neurourol Urodyn"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.05.008","article-title":"Meningitis-retention syndrome: clinical features, frequency and prognosis","volume":"390","author":"Hiraga A","year":"2018","unstructured":"Hiraga A, Kuwabara S. Meningitis-retention syndrome: clinical features, frequency and prognosis. J Neurol Sci. 2018, 390:261-4. 10.1016\/j.jns.2018.05.008","journal-title":"J Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5213\/inj.2015.19.3.207","article-title":"Meningitis-retention syndrome","volume":"19","author":"Basoulis D","year":"2015","unstructured":"Basoulis D, Mylona M, Toskas P, Tsilingiris D, Fytili C. Meningitis-retention syndrome. Int Neurourol J. 2015, 19:207-9. 10.5213\/inj.2015.19.3.207","journal-title":"Int Neurourol J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220903","article-title":"Cystometrography of meningitis-retention syndrome","volume":"2017","author":"Tanaka Y","year":"2017","unstructured":"Tanaka Y, Satomi K. Cystometrography of meningitis-retention syndrome. BMJ Case Rep. 2017, 2017:10.1136\/bcr-2017-220903","journal-title":"BMJ Case Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322009000900017","article-title":"Unusual combination of reversible splenial lesion and meningitis-retention syndrome in aseptic meningomyelitis","volume":"64","author":"Tascilar N","year":"2009","unstructured":"Tascilar N, Aydemir H, Emre U, Unal A, Atasoy HT, Ekem S. Unusual combination of reversible splenial lesion and meningitis-retention syndrome in aseptic meningomyelitis. Clinics (Sao Paulo). 2009, 64:932-7. 10.1590\/S1807-59322009000900017","journal-title":"Clinics (Sao Paulo)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-159","article-title":"Acute urinary retention in a 23-year-old woman with mild encephalopathy with a reversible splenial lesion: a case report","volume":"5","author":"Kitami M","year":"2011","unstructured":"Kitami M, Kubo SI, Nakamura S, Shiozawa S, Isobe H, Furukawa Y. Acute urinary retention in a 23-year-old woman with mild encephalopathy with a reversible splenial lesion: a case report. J Med Case Reports. 2011, 5:159. 10.1186\/1752-1947-5-159","journal-title":"J Med Case Reports"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5348\/ijcri-2011-11-64-CR-2","article-title":"Isolated splenial lesion in the corpus callosum in combination with urinary retention in a case of aseptic meningoencephalitis","volume":"2","author":"Saluja M","year":"2011","unstructured":"Saluja M, Mcgrath N. Isolated splenial lesion in the corpus callosum in combination with urinary retention in a case of aseptic meningoencephalitis. Int J Case Rep Imag. 2011, 2:6-9. 10.5348\/ijcri-2011-11-64-CR-2","journal-title":"Int J Case Rep Imag"},{"key":"ref34","article-title":"Ataxia after vaccination in United States, a report from the CDC\/FDA Vaccine Adverse Event Reporting System [1990-2010] (P05.016)","volume":"78","author":"Sheikh Z","year":"2012","unstructured":"Sheikh Z, Abukwaik W, Souayah N. Ataxia after vaccination in United States, a report from the CDC\/FDA Vaccine Adverse Event Reporting System [1990-2010] (P05.016). Neurology. 2012, 78:5-16.","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81554-neurological-conditions-following-covid-19-vaccinations-chance-or-association","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:03Z","timestamp":1707507843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81554-neurological-conditions-following-covid-19-vaccinations-chance-or-association"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.21919","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}